The Jordan Food and Drug Administration (JFDA) is Jordan’s national regulator for drugs, biologics, medical devices, and clinical research, and it is the competent authority that must approve a clinical trial before it can proceed in the country. Within JFDA, approval decisions for interventional clinical trials are made by the Clinical Studies Committee (CSC), a 12-member body chaired by the Director General of JFDA that reviews trial applications after the protocol has already cleared a local institutional review board (IRB) or research ethics committee. This guide covers how the CSC is constituted, how the two-track approval sequence works, what a complete application requires, and what sponsors should actually expect on timeline — including a correction to a figure that circulates online conflating clinical-trial approval with a completely different JFDA process.
What JFDA Is and What the Clinical Studies Committee Does
JFDA sits under Jordan’s Ministry of Health and regulates the full lifecycle of pharmaceuticals and clinical research in the country, from good manufacturing practice inspection through drug marketing authorization and clinical trial oversight. Clinical trial approval specifically is delegated to the Clinical Studies Committee, established under Jordan’s Clinical Studies Law (Law No. 2 of 2011). The CSC is a standing, multi-disciplinary review body — not a single JFDA department signing off administratively — built to bring in expertise JFDA staff alone would not have: pharmacology, biostatistics, clinical pharmacy, and practicing clinicians alongside JFDA’s own drug-directorate leadership. Its membership includes the JFDA Director General (who chairs the committee), the Director of the Drug Directorate, the Head of the Clinical Studies Division, a pharmacist from the Drug Directorate, two clinicians (one appointed by the Minister of Health and one internist nominated by the Jordan Medical Association’s Physicians Labor Board), the Head of Pharmacy at the Royal Medical Services, and five additional academic and private-sector representatives covering pharmacokinetics, analytical chemistry, biostatistics, clinical pharmacy, and pharmacology. Membership terms run two years and are renewable.
The Approval Sequence: Local Ethics Review, Then CSC Review
Jordan uses the same two-track model most ICH-aligned jurisdictions use: ethics approval and regulatory approval are separate, both mandatory, and neither substitutes for the other. In practice this means a sponsor first submits the protocol, informed consent materials, and investigator’s brochure to the site’s (or a central) institutional review board / research ethics committee for local ethical clearance. Only once that local IRB approval is in hand does the application go to JFDA’s Clinical Studies Committee for regulatory review of the trial itself — the CSC’s remit covers the scientific and regulatory adequacy of the protocol, the investigational product’s quality and safety documentation, and the suitability of the proposed site(s) and investigator(s), on top of confirming ethics clearance is already documented. A trial cannot begin enrolling in Jordan until both approvals exist. This mirrors the sequencing used in neighboring jurisdictions — see CASRAI’s guides to Israel’s Helsinki Committee pathway and Saudi Arabia’s SFDA/SCTR pathway for comparison.
How Long CSC Review Actually Takes — and a Common Mix-Up to Avoid
A specific figure that gets repeated in secondary regulatory-affairs summaries is a “210-calendar-day” JFDA review target. That number is real, but it does not describe clinical-trial approval: it is JFDA’s published overall target for drug marketing-authorization review (registration of a finished pharmaceutical product for sale), built from a roughly 180-calendar-day (about 122 working-day) technical review period plus a separate pricing-review step of around 30 calendar days. That is a different regulatory transaction — a completed drug seeking market entry, not an investigational product seeking permission to be studied in humans — and applying it to CSC clinical-trial review overstates how long the trial-approval step itself takes and, more importantly, cites the wrong process entirely.
JFDA does not publish a single fixed statutory day-count specifically for CSC clinical-trial review the way it does for marketing-authorization review, so sponsors should not treat any specific figure as an official regulatory guarantee. Regulatory-affairs practitioners and CROs operating in Jordan generally describe CSC review, once a complete dossier with documented local IRB approval is submitted, as running on the order of several weeks to a few months, with the local IRB step typically proceeding on a comparable timeframe to institutional ethics review elsewhere in the region. Actual duration depends heavily on dossier completeness, whether the CSC requests clarifications (which restarts the practical clock while the sponsor responds), trial complexity and phase, and the committee’s meeting cadence. Sponsors planning a Jordan site should budget conservatively, build in time for at least one round of committee queries, and confirm current expectations directly with JFDA or a Jordan-based regulatory consultant rather than relying on a single cited number — including the 210-day figure, which belongs to a different approval altogether.
What a Clinical Trial Application to the CSC Requires
A complete submission to the Clinical Studies Committee typically includes the trial protocol and any amendments, the investigator’s brochure, evidence of local IRB/ethics committee approval, the informed consent form(s) in Arabic (and English where applicable), investigator and site qualification documentation (CVs, site facilities, GCP training records), the investigational product’s quality/manufacturing documentation (or, for products already registered elsewhere, relevant certificates such as a certificate of pharmaceutical product), an insurance/indemnity arrangement covering trial subjects, and the sponsor’s or local CRO’s regulatory correspondence contact in Jordan. Sponsors conducting multi-country trials commonly manage this alongside IND-equivalent submissions in other jurisdictions and should expect Jordan-specific formatting and Arabic-language requirements even where the underlying dossier is otherwise harmonized.
Ongoing Obligations After CSC Approval
CSC approval is not a one-time event that ends JFDA’s involvement. Approved trials remain subject to pharmacovigilance and safety reporting obligations, including expedited reporting of serious adverse events and suspected unexpected serious adverse reactions consistent with international Good Clinical Practice norms. Protocol amendments, changes to the investigator’s brochure, new safety information, and changes of principal investigator or site typically require CSC notification or re-approval before implementation, and periodic progress or safety updates may be requested for longer-running studies. Sponsors should treat the CSC relationship as continuing for the life of the trial, not just at the approval gate.
Jordan in the Regional Regulatory Context
Jordan’s two-track model (independent ethics review plus a dedicated national scientific/regulatory committee) is broadly consistent with how other MENA-region regulators structure clinical-trial approval, even though committee composition, statutory timelines, and registry requirements differ by country. For comparison, Israel’s Ministry of Health pathway runs through institutional and central Helsinki Committees before Ministry authorization (see CASRAI’s Israel clinical trials guide), while Saudi Arabia’s SFDA combines authorization with mandatory registration in the Saudi Clinical Trials Registry (see CASRAI’s SFDA/SCTR guide). Sponsors running regional multi-country trials should map each country’s sequencing and documentation separately rather than assuming a single regional timeline or dossier will satisfy every regulator.
Frequently Asked Questions
Does JFDA approval replace the need for local IRB approval in Jordan?
No. Local IRB or research ethics committee approval and JFDA/CSC regulatory approval are separate, both mandatory, and are obtained in sequence — local ethics approval first, then CSC review. Neither substitutes for the other.
Is the “210-day” JFDA timeline the correct figure to cite for clinical trial approval?
No. The 210-calendar-day target (roughly 180 days of technical review plus about 30 days of pricing review) is JFDA’s published target for drug marketing-authorization review of a finished pharmaceutical product, not for Clinical Studies Committee review of an investigational trial. The two are different regulatory processes and citing one for the other is a common but incorrect conflation.
Who sits on Jordan’s Clinical Studies Committee?
The CSC has 12 members chaired by the JFDA Director General, and includes JFDA’s Drug Directorate Director and Clinical Studies Division head, a Drug Directorate pharmacist, two clinicians, the Royal Medical Services’ Head of Pharmacy, and five academic/private-sector specialists covering pharmacokinetics, analytical chemistry, biostatistics, clinical pharmacy, and pharmacology. Terms are two years, renewable.
What law governs clinical trial approval in Jordan?
Jordan’s Clinical Studies Law (Law No. 2 of 2011) is the statutory basis for the Clinical Studies Committee and its authority to review and approve clinical trial applications.
Can a trial enroll subjects in Jordan before CSC approval is issued?
No. Both local ethics approval and CSC approval must be in place before enrollment begins; proceeding without either is a regulatory violation in Jordan, consistent with the two-track model used across ICH-aligned jurisdictions.
